Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase

Sy SKB et al. Clin Pharmacokinet, February 2026 (epub ahead of print)

• Share
• Tweet
• Share
• Share